



CODEN [USA]: IAJ PBB

ISSN: 2349-7750

**INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES**<http://doi.org/10.5281/zenodo.2604609>Available online at: <http://www.iajps.com>

Research Article

**STUDY TO KNOW THE IN VIVO SAFETY AND EFFICACY
OF QUININE-DOXYCYCLINE GIVEN IN COMBINATION
FOR THE TREATMENT OF ACUTE PLASMODIUM
FALCIPARUM MALARIA**¹Dr. Rabia Naeem, ²Dr. Namra Mushtaq, ³Dr. Maria Mubarak^{1,2}CMH Lahore Medical College and Institute of Dentistry, Lahore, ³Akhtar Saeed Medical and Dental Collge, Lahore.**Article Received:** January 2019**Accepted:** February 2019**Published:** March 2019**Abstract:**

Objective: To know the in vivo efficacy and adverse effects of quinine doxycycline in malaria caused by *Plasmodium (P.) falciparum*. **Study Design:** A prospective observational study.

Place and Duration: In the medicine Unit II of Jinnah Hospital Lahore for one year duration from September 2017 to September 2018. **Methodology:** Three hundred and thirty-seven patients with positive *P. falciparum* in the malaria test met the selection criteria and were included in the study. The mean, minimum and maximum values were calculated with the standard age deviation, the time to remove the fever from the malaria parasite index and the duration of the parasites. In addition, the frequency of various side effects and deaths observed during this study was also calculated. **Results:** Of the 337 subjects, 256 had *P. falciparum* and 81 had mixed infections involving both *P. falciparum* and *P. vivax*. The mean time to remove fever in cases infected with *P. falciparum* and mixed infection was 46.3 hours and 44.16 hours, respectively. The mean elimination times of parasites in subjects infected with *P. falciparum* and mixed infection were 70.32 hours and 68 hours, respectively. Approximately 3.3% of subjects had mild to moderate side effects such as tinnitus, prolongation of QT interval and vomiting. The mortality rate observed in this study was around 0.6%. **Conclusion:** Combination therapy with doxycycline can be used safely and effectively in the treatment of *P. falciparum* malaria.

Key words: doxycycline quinine combination, malaria, *Plasmodium falciparum*, mixed infection.

Corresponding author:**Dr. Rabia Naeem,**

CMH Lahore Medical College and Institute of Dentistry, Lahore.

QR code



Please cite this article in press Rabia Naeem et al., Study to Know the in Vivo Safety and Efficacy of Quinine-Doxycycline Given in Combination for the Treatment of Acute Plasmodium Falciparum Malaria., Indo Am. J. P. Sci, 2019; 06(03).

INTRODUCTION:

Malaria is the most important parasitic infection in the world and is one of the main causes of morbidity and mortality. Despite years of continuous efforts, more than two billion people continue to be a threat and one to three million people die each year [1-3]. Among the four types of malaria parasites, protozoan plasmodium (*P.*) falciparum represents most cases of morbidity and mortality. Combined infections with more than one parasite species usually involve *P.* falciparum with a severe risk of malaria [4-6]. The increased prevalence of multidrug-resistant *P.* falciparum malaria is a serious threat to public health, especially from the global control of malaria in poor countries such as malaria. The artemisinin based combinations like Artesuna- teamodiaquine, artemether-lumefantrine (Coartem), Pyronaridine-artesunate and piperaquinedihydroartemisinin-trimetoprim (Artecom) etc. as well as the non-artemisinin- based combinations like Mefloq-uine-sulfadoxinepyri- methamine (Fansimet), Quinine-Doxycycline and Atovaquone-proguanil (Malarone) etc. have been suggested in different studies [7]. It has been used in combination with an antibiotic such as doxycycline or tetracycline as a preferred treatment in severe or complicated falciparum malaria, with the emergence of sporadic resistance to traditional quinine monotherapy in Southeast Asia and Western Oceania. Adverse reactions such as tinnitus therapy, tinnitus, nausea, vomiting, dizziness, myocarditis, hypotension, hypoglycemia and sometimes acute renal failure have been reported in the literature. Because the recent reports on the gradual decline in the activity of quinine and *P.* falciparum are resistant to recommendations for most combinations of antimalarial drug and artemisinin based (about 5 to 6 times more expensive) combinations [8-9]. The use of a combination of the quinoline octanol line tested over time became questionable. It is still accepted as the treatment of choice in the latest malaria models in the UK.

MATERIALS AND METHODS:

This prospective observational study was held in the medicine Unit II of Jinnah Hospital Lahore for one year duration from September 2017 to September 2018. The criteria included (12-60 age group, malaria parasite film showing *P.* falciparum) in this study after informed consent was obtained. The history of swallowing of anti-marital medications during pregnancy or during other illnesses has been

excluded. After enrollment, all participants were hospitalized for seven days with combination therapy with quinine doxycycline (three doses of quinine 30 mg / kg, 200 mg doxycycline twice daily in two divided doses), paracetamol and dimenhydrinate, respectively, for symptoms of fever / headache, Nausea / dizziness respectively. The drugs or intravenous fluids were given only as prescribed by the treating physician. Signs and symptoms, drug history and side effects were recorded daily. Routine physical examinations and laboratory tests were performed periodically until the seventh day. Blood stains were taken twice daily until malaria disappeared, followed once a week or clinically justified once a day. The efficacy of therapy in each subject was determined by the elimination of fever and elimination of the parasite. The duration of the clearance was defined as the time until the temperature was $<37.4^{\circ}\text{C}$ and remained there for at least 48 hours. The duration of the elimination of the parasite was defined as the time from the beginning of treatment to the first negative blood contamination for asexual stages, which remained negative for an additional 24 hours. All information was recorded in a pre-designed Performa. All patients were evaluated on a daily basis to report adverse events that were initially new during treatment or that were severely violated after administration of study drugs. Considering that the relationship with treatment was definite or probable by a study physician, an adverse event was thought to be drug dependent. Data were entered and analyzed in SPSS 18.0 software. The mean, minimum and maximum values were calculated with the standard deviation of time of extinction of fever and time of disappearance of parasites. The frequency of various side effects and deaths observed during this study was calculated.

RESULTS:

In total, three hundred and thirty-seven subjects met the selection criteria and were included in the study. Of these, 337,256 had *P.* falciparum infection, while 81 had mixed infection (*P.* falciparum and *P.* vivax combination). The mean age of the participants was 27.9 years between 12 and 51 years. In this study, all subjects were male only. The mean malaria parasite ratio was 1.1 in *P.* falciparum and 1.2 in mixed infection. The mean time to eliminate fever in individuals with *P.* falciparum infection and mixed infection was 46.3 hours and 44.16 hours, respectively.

Table-I: Main parasite clearance time in *P. falciparum* was 70.32 hours

Parameters	<i>P.falciparum</i> n = 256	Mixed infectionn = 81
Age (years)	Mean 28.3 Range 12-51 Standard deviation 6.96	Mean 26.62 Range 14-43 Standard deviation 5.7
Malarial parasite index	Mean 1.1 Range Upto 20 Standard deviation 1.1	Mean 1.2 Range Upto 18 Standard deviation 1.21
Fever clearance time (hours)	Mean 46.3 Range 12-86 Standard deviation 1.2	Mean 44.16 Range 12-104 Standard deviation 1.41
Parasite clearance time (hours)	Mean 70.12 Range 24-136 Standard deviation 1.3	Mean 68 Range 24-130 Standard deviation 1.48
Adverse effects (n)	Tinnitus 4 ECG changes 2 Vomiting 2	Tinnitus 2 ECG changes 1 Vomiting none

The mean elimination time of the parasite in individuals with *P. falciparum* infection and mixed infection was 70.32 hours and 68 hours, respectively. Approximately 96.7% of the individuals in this study tolerated the combination therapy of quinine with doxycycline without any side effects of quinine. Only 3.3% (11/337) of the subjects developed mild to moderate side effects, such as tinnitus, prolongation of the QT interval, and vomiting. In this study, approximately 0.78% (2/256) of patients with *P. falciparum* infection died.

DISCUSSION:

This study demonstrated the in vivo efficacy and safety of combination therapy with Quinine doxycycline in malaria caused by *P. falciparum* in this part of the world in the background of reports showing an increase in resistance and severe adverse effects. This study reported that the mean elimination time of fever in subjects infected with *P. falciparum* was 46.3 hours and this time was much shorter than that observed in some of the international studies reporting that the reported quinine was between 55 and 107 hours, several studies have shown that there is almost a similar period or less¹⁰. This significant difference in mean fever removal time in the currently documented data may be due to the difference in sample size because most studies involve fewer participants and their fever is not under control. The mean elimination time of the reported fever in this study was slightly lower than the previous trials evaluating the effectiveness of the artemisinin-based combination, which is 80 to 108

hours [11-12]. In mixed infection involving both *P. falciparum* and *P. vivax*, the mean elimination time of the fever was almost unchanged, ie, 44.16 h. None of the studies in the literature evaluated the effect of mixed infection on the mean duration of clearance [13]. In this study, the mean elimination time for parasites was 70.32 hours in people infected with *P. falciparum*. This result was very variable in different trials. The time indicated in this study is almost identical to one of the trials and is shorter than the time specified in some other studies. Some of the studies reported that the mean elimination time of the average parasite was between 22.4 and 51.9 hours [14]. These resulting changes may occur in the elimination due to the reasons previously mentioned or the difference in the resistance between the regions. In this study, the mean elimination time of the parasite was almost similar to an assay that evaluated the efficacy of the artemisinin-based combination [15]. The mean elimination time of parasites in the mixed infection caused by *P. falciparum* and *P. vivax* was almost the same, ie 68 hours. None of the studies determined the effect of mixed infection on the elimination period of parasites. None of the subjects included in this study had a severe adverse reaction with quinine-based combination. Only mild to moderate side effects were observed in 3.3% of individuals and were much lower than those observed in previous studies. These side effects were successfully managed by reducing the dose of quinine without compromising the efficacy of the treatment. In these studies, approximately 1.8% of the subjects developed

tinnitus compared to 89% in previous studies.

CONCLUSION:

Combination therapy with Quinine doxycycline can be used safely and effectively in the treatment of malaria caused by *P. falciparum*, especially in low socioeconomic communities such as the majority of the population in this part of the world.

REFERENCES:

1. Yeo, T. W., J. B. Weinberg, D. A. Lampah, E. Kenangalem, P. Bush, Y. Chen, R. N. Price et al. "Glycocalyx Breakdown is Associated with Severe Disease and Fatal Outcome in Plasmodium falciparum Malaria." *Clinical Infectious Diseases*(2019).
2. Diallo, D. A., M. A. Baraïka, A. Guindo, A. K. Dembélé, and N. D. Moukodoum. "Plasmodium falciparum Malaria Frequency; Pfdhps and Pfdhfr Polymorphisms Associated with Severe Resistance in Febrile Sick Cell Children Receiving Intermittent Treatment with Sulfadoxine-Pyrimethamine in a West African Country." *J Biomed Res Prac* 3, no. 1 (2019): 100014.
3. Leang, Rithea, Melissa Mairet-Khedim, Huch Chea, Rekol Huy, Nimol Khim, Denis Mey Bouth, Maria Dorina Bustos, Pascal Ringwald, and Benoit Witkowski. "Efficacy and safety of pyronaridine-artesunate plus single-dose primaquine for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Cambodia." *Antimicrobial agents and chemotherapy*(2019): AAC-02242.
4. Intharabut, Benjamas, Hugh W. Kingston, Ketsanee Srinamon, Elizabeth A. Ashley, Mallika Imwong, Mehul Dhorda, Charles Woodrow et al. "Artemisinin resistance and stage dependency of parasite clearance in Falciparum malaria." *Journal of Infectious Diseases* (2019).
5. Gleeson, Patrick J., John A. O'Regan, Teresa McHale, Helen Tuite, Louise Giblin, and Donal Reddan. "Acute interstitial nephritis with podocyte foot-process effacement complicating Plasmodium falciparum infection." *Malaria journal* 18, no. 1 (2019): 58.
6. Rajahram, Giri S., Daniel J. Cooper, Timothy William, Matthew J. Grigg, Nicholas M. Anstey, and Bridget E. Barber. "Deaths from Plasmodium knowlesi malaria: case series and systematic review." *Clinical Infectious Diseases* (2019).
7. Hviid, Lars, Cecilia Smith-Togobo, and Benjamin E. Willcox. "Human Vδ1+ T cells in the immune response to Plasmodium falciparum infection." *Frontiers in immunology* 10 (2019).
8. Acharya, Pragyan, Atreyi Pramanik, Charandeep Kaur, Kalpana Sinha, Amit Dinda, Jhuma Sankar, Arvind Bagga, Sanjay Agarwal, Aditi Sinha, and Geetika Singh. "Renal Localization of Plasmodium vivax and Zoonotic Monkey Parasite Plasmodium knowlesi in Malaria Associated Acute Kidney Injury." *bioRxiv* (2019): 544726.
9. Achieng, Angela O., Bernard Guyah, Qiuying Cheng, John M. Ong'echa, Collins Ouma, Christophe G. Lambert, and Douglas Jay Perkins. "Molecular Basis of Reduced LAIR1 Expression in Childhood Severe Malarial Anemia: Implications for Leukocyte Inhibitory Signalling." *Available at SSRN 3334999*(2019).
10. Brown, Denver D., Sonia Solomon, Daniele Lerner, and Marcela Del Rio. "Malaria and acute kidney injury." *Pediatric Nephrology* (2019): 1-6.
11. Sondo, Paul, Karim Derra, Thierry Lefevre, Seydou Diallo-Nakanabo, Zekiba Tarnagda, Odile Zampa, Adama Kazienga et al. "Genetically diverse Plasmodium falciparum infections, within-host competition and symptomatic malaria in humans." *Scientific reports* 9, no. 1 (2019): 127.
12. Mehlotra, Rajeev K., Rosalind E. Howes, Estee Y. Cramer, Riley E. Tedrow, Tovonahary A. Rakotomanga, Stephanie Ramboarina, Arsène C. Ratsimbasoa, and Peter A. Zimmerman. "Plasmodium falciparum Parasitemia and Band Sensitivity of the SD Bioline Malaria Ag Pf/Pan Rapid Diagnostic Test in Madagascar." *The American journal of tropical medicine and hygiene* (2019): tpm181013.
13. Messina, V., Loizzo, S., Travaglione, S., Bertuccini, L., Condello, M., Superti, F., Guidotti, M., Alano, P., Silvestrini, F. and Fiorentini, C., 2019. The bacterial protein CNF1 as a new strategy against Plasmodium falciparum cytoadherence. *PLoS one*, 14(3), p.e0213529.
14. Pryce, Joseph, and Paul Hine. "Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria." *Cochrane Database of Systematic Reviews* 1 (2019).
15. Arora, Aanchal, Manasa Mudalagiri, Deepali Sharma, and Yogesh Chandra Porwal. "Myocarditis with sinus exit block: A rare presentation of Plasmodium vivax malaria." *Indian Journal of Medical Specialities* 10, no. 1 (2019): 39.